Mediar Therapeutics
PrivateLast Round
Series B
Jan 7, 2026
Est. Valuation
$230.3M
Total Funding Raised
$181M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mediar Therapeutics is a biotechnology company developing innovative antibody-based therapies aimed at halting and reversing fibrotic activity in chronic organ damage.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mediar Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Mediar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 7, 2026 | ||||
| Series A | Mar 15, 2023 | ||||
| Seed | Mar 17, 2021 |
Mediar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Seed |
| Gimv | Series B, Series A |
| Asahi Kasei Pharma Ventures | Series B |
| Amplitude Ventures | Series B |
| Mass General Brigham Innovation | Series A, Seed |
| Intermediate Capital Group | Series B |
| Viva Biotech | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
$76M round completed.
- Mar 15, 2023
$85M round led by Novartis and Sofinnova Partners.
Mediar Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mediar Therapeutics's valuation, stock price, and market status.